Nörodejeneratif Hastalıklar ve Yoğun Bakımda Yönetimi
Özet
Nörodejenerasyon, nöronlarda görülen ilerleyici yapı veya fonksiyon kaybıdır. İlerleyici karakteri zamanla semptomların ve hasarın artmasına neden olur. Bu süreç beyindeki, omurilikteki ve periferik sinir sistemindeki nöronları etkiler. Parkinson, Alzheimer ve Huntington hastalığı en yaygın nörodejeneratif hastalıklar arasındadır. Nörodejenerasyonu geri çeviren veya engelleyen bir tedavi henüz bulunamamıştır, mevcut tedavi yaklaşımları bu hastalıkların ilerlemesini yavaşlatmaya odaklanmaktadır. Ancak gen terapileri bu alanda umut vaat etmektedir. Nörodejeneratif hastalıkların ileri aşamalarında hastalar yoğun bakım ve palyatif bakım desteğine ihtiyaç duyabilir.
Neurodegeneration refers to the gradual loss of structure and function in neurons, leading to increased symptoms and damage over time. This process affects neurons in the brain, spinal cord, and peripheral nervous system. Parkinson's, Alzheimer's, and Huntington's disease are among the most common neurodegenerative diseases. Current treatment approaches focus on slowing down the progression of these diseases, as a complete reversal or prevention of neurodegeneration is yet to be discovered. However, gene therapies show promise in this field. In advanced stages of neurodegenerative diseases, patients may require intensive care and palliative care support.
Referanslar
Lamptey, Richard N L et al. “A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.” International journal of molecular sciences vol. 23,3 1851. 6 Feb. 2022, doi:10.3390/ijms23031851
Wakabayashi, Koichi et al. “Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain.” Acta neuropathologica vol. 120,1 (2010): 1-12. doi:10.1007/s00401-010-0706-x
Low, James Alvin, and Esther Ho. “Managing Ethical Dilemmas in End-Stage Neurodegenerative Diseases.” Geriatrics (Basel, Switzerland) vol. 2,1 8. 20 Jan. 2017, doi:10.3390/geriatrics2010008
Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010 Mar;14(3):457-87. doi: 10.1111/j.1582-4934.2010.01010.x. Epub 2010 Jan 11. PMID: 20070435; PMCID: PMC3823450.
Gitler, Aaron D et al. “Neurodegenerative disease: models, mechanisms, and a new hope.” Disease models & mechanisms vol. 10,5 (2017): 499-502. doi:10.1242/dmm.030205
Rapp T, Chauvin P, Costa N, Molinier L. Health economic considerations in neurodegenerative disorders. In: Saba L (ed.), Imaging in Neurodegenerative Disorders. online ed. Oxford: Oxford Academic; 2015. p. 42–53. doi: 10.1093/med/9780199671618.003.0004
Eric R. Kandel, John D. Koester, Sarah H. Mack, Steven A. Siegelbaum Principles of Neural Science Sixth Edition McGraw Hill Professional, 5 Nis 2021 sayfa:1556
Bredesen, Dale E et al. “Cell death in the nervous system.” Nature vol. 443,7113 (2006): 796-802. doi:10.1038/nature05293
Mosley, Philip E et al. “Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature.” Journal of geriatric psychiatry and neurology vol. 30,5 (2017): 235-252. doi:10.1177/0891988717720302
JPND Neurodegenerative Disease Research. from https://neurodegenerationresearch.eu/(Accessed 15th April 2023).
Reilly, Aoife et al. “Curing SMA: Are we there yet?.” Gene therapy vol. 30,1-2 (2023): 8-17. doi:10.1038/s41434-022-00349-y
Zanetti, O., S. B. Solerte, and F. Cantoni. "Life expectancy in Alzheimer's disease (AD)." Archives of gerontology and geriatrics 49 (2009): 237-243.
Mészáros, Lisa et al. “Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.” International journal of molecular sciences vol. 21,8 2775. 16 Apr. 2020, doi:10.3390/ijms21082775
Bello-Haas, Vanina Dal. “Physical therapy for individuals with amyotrophic lateral sclerosis: current insights.” Degenerative neurological and neuromuscular disease vol. 8 45-54. 16 Jul. 2018, doi:10.2147/DNND.S146949
Ben Hadj Salem, O. “Neurocritical care for neurological incapacitated patients.” Revue neurologique vol. 178,1-2 (2022): 105-110. doi:10.1016/j.neurol.2021.08.003
Pandharipande, P P et al. “Long-term cognitive impairment after critical illness.” The New England journal of medicine vol. 369,14 (2013): 1306-16. doi:10.1056/NEJMoa1301372
Smith, Martin, and Geert Meyfroidt. “Critical illness: the brain is always in the line of fire.” Intensive care medicine vol. 43,6 (2017): 870-873. doi:10.1007/s00134-017-4791-3
Kiphuth, Ines C et al. “Retrospective agreement and consent to neurocritical care is influenced by functional outcome.” Critical care (London, England) vol. 14,4 (2010): R144. doi:10.1186/cc9210
Kiphuth, Ines C et al. “Predictors for good functional outcome after neurocritical care.” Critical care (London, England) vol. 14,4 (2010): R136. doi:10.1186/cc9192
Weintraub, Daniel et al. “Management of psychiatric and cognitive complications in Parkinson's disease.” BMJ (Clinical research ed.) vol. 379 e068718. 24 Oct. 2022, doi:10.1136/bmj-2021-068718
Freeman, W. D., Tan, K. M., Glass, G. A., Linos, K., Foot, C., & Ziegenfuss, M. (2007). ICU management of patients with Parkinson's disease or Parkinsonism. Current Anaesthesia and Critical Care, 18(5-6), 227-236. https://doi.org/10.1016/j.cacc.2007.09.007
Altman, Kenneth W et al. “Dysphagia in stroke, neurodegenerative disease, and advanced dementia.” Otolaryngologic clinics of North America vol. 46,6 (2013): 1137-49. doi:10.1016/j.otc.2013.08.005
Robert, R., Goldberg, M. Palliative, palliative or palliative?. Crit Care 25, 203 (2021). https://doi.org/10.1186/s13054-021-03633-2
Robinson, Maisha T, and Robert G Holloway. “Palliative Care in Neurology.” Mayo Clinic proceedings vol. 92,10 (2017): 1592-1601. doi:10.1016/j.mayocp.2017.08.003
Referanslar
Lamptey, Richard N L et al. “A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.” International journal of molecular sciences vol. 23,3 1851. 6 Feb. 2022, doi:10.3390/ijms23031851
Wakabayashi, Koichi et al. “Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain.” Acta neuropathologica vol. 120,1 (2010): 1-12. doi:10.1007/s00401-010-0706-x
Low, James Alvin, and Esther Ho. “Managing Ethical Dilemmas in End-Stage Neurodegenerative Diseases.” Geriatrics (Basel, Switzerland) vol. 2,1 8. 20 Jan. 2017, doi:10.3390/geriatrics2010008
Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010 Mar;14(3):457-87. doi: 10.1111/j.1582-4934.2010.01010.x. Epub 2010 Jan 11. PMID: 20070435; PMCID: PMC3823450.
Gitler, Aaron D et al. “Neurodegenerative disease: models, mechanisms, and a new hope.” Disease models & mechanisms vol. 10,5 (2017): 499-502. doi:10.1242/dmm.030205
Rapp T, Chauvin P, Costa N, Molinier L. Health economic considerations in neurodegenerative disorders. In: Saba L (ed.), Imaging in Neurodegenerative Disorders. online ed. Oxford: Oxford Academic; 2015. p. 42–53. doi: 10.1093/med/9780199671618.003.0004
Eric R. Kandel, John D. Koester, Sarah H. Mack, Steven A. Siegelbaum Principles of Neural Science Sixth Edition McGraw Hill Professional, 5 Nis 2021 sayfa:1556
Bredesen, Dale E et al. “Cell death in the nervous system.” Nature vol. 443,7113 (2006): 796-802. doi:10.1038/nature05293
Mosley, Philip E et al. “Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature.” Journal of geriatric psychiatry and neurology vol. 30,5 (2017): 235-252. doi:10.1177/0891988717720302
JPND Neurodegenerative Disease Research. from https://neurodegenerationresearch.eu/(Accessed 15th April 2023).
Reilly, Aoife et al. “Curing SMA: Are we there yet?.” Gene therapy vol. 30,1-2 (2023): 8-17. doi:10.1038/s41434-022-00349-y
Zanetti, O., S. B. Solerte, and F. Cantoni. "Life expectancy in Alzheimer's disease (AD)." Archives of gerontology and geriatrics 49 (2009): 237-243.
Mészáros, Lisa et al. “Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.” International journal of molecular sciences vol. 21,8 2775. 16 Apr. 2020, doi:10.3390/ijms21082775
Bello-Haas, Vanina Dal. “Physical therapy for individuals with amyotrophic lateral sclerosis: current insights.” Degenerative neurological and neuromuscular disease vol. 8 45-54. 16 Jul. 2018, doi:10.2147/DNND.S146949
Ben Hadj Salem, O. “Neurocritical care for neurological incapacitated patients.” Revue neurologique vol. 178,1-2 (2022): 105-110. doi:10.1016/j.neurol.2021.08.003
Pandharipande, P P et al. “Long-term cognitive impairment after critical illness.” The New England journal of medicine vol. 369,14 (2013): 1306-16. doi:10.1056/NEJMoa1301372
Smith, Martin, and Geert Meyfroidt. “Critical illness: the brain is always in the line of fire.” Intensive care medicine vol. 43,6 (2017): 870-873. doi:10.1007/s00134-017-4791-3
Kiphuth, Ines C et al. “Retrospective agreement and consent to neurocritical care is influenced by functional outcome.” Critical care (London, England) vol. 14,4 (2010): R144. doi:10.1186/cc9210
Kiphuth, Ines C et al. “Predictors for good functional outcome after neurocritical care.” Critical care (London, England) vol. 14,4 (2010): R136. doi:10.1186/cc9192
Weintraub, Daniel et al. “Management of psychiatric and cognitive complications in Parkinson's disease.” BMJ (Clinical research ed.) vol. 379 e068718. 24 Oct. 2022, doi:10.1136/bmj-2021-068718
Freeman, W. D., Tan, K. M., Glass, G. A., Linos, K., Foot, C., & Ziegenfuss, M. (2007). ICU management of patients with Parkinson's disease or Parkinsonism. Current Anaesthesia and Critical Care, 18(5-6), 227-236. https://doi.org/10.1016/j.cacc.2007.09.007
Altman, Kenneth W et al. “Dysphagia in stroke, neurodegenerative disease, and advanced dementia.” Otolaryngologic clinics of North America vol. 46,6 (2013): 1137-49. doi:10.1016/j.otc.2013.08.005
Robert, R., Goldberg, M. Palliative, palliative or palliative?. Crit Care 25, 203 (2021). https://doi.org/10.1186/s13054-021-03633-2
Robinson, Maisha T, and Robert G Holloway. “Palliative Care in Neurology.” Mayo Clinic proceedings vol. 92,10 (2017): 1592-1601. doi:10.1016/j.mayocp.2017.08.003
